27 March 2026

Important update on alogabat, an investigational therapy in development for Angelman syndrome

Dear Angelman syndrome community,

In line with our commitment to transparently communicate about the Angelman syndrome (AS) program with alogabat and your request to receive relevant updates in a timely manner, today we are writing to share news about the Phase 2 ALDEBARAN study. We want to start by expressing our deepest gratitude to each of you. Your dedication and commitment to advancing Angelman research and the ALDEBARAN study have been invaluable, and we are profoundly thankful for the collaboration of the families, patient advocacy groups, investigators and clinical research sites staff, and the broader AS community. Your resilience and collaboration have been the cornerstone of this journey.

The ALDEBARAN study is testing the safety of alogabat in 48 participants with deletion AS aged 5-17 years old. Alogabat is designed to target GABAA α5 receptors, which are involved with certain genes affected by deletion AS.

Results from the ALDEBARAN study showed that alogabat was safe and well tolerated in study participants. However, no change was seen in brain activity patterns, as measured by EEG. which suggests lack of effect on the GABA component of the disease. Due to the results of the study, Roche will stop further development of alogabat for Angelman syndrome. Data will be presented at a future science session to help inform other drug development approaches.

We understand that this update may be disappointing. Families with a child who participated in the ALDEBARAN study should already have heard this news from their study physician.

Thank you to the study participants and families once again for your unwavering support of research. Every trial contributes to broader understanding of AS, and research is only possible with your partnership.

Sincerely,

Shady Sedhom Global Patient Partnership Leader	**Julie M Burns** Director, U.S. Patient Advocacy Relations